Table 2 Subgroup analyses of overall survival (OS) and progression-free survival (PFS)
Outcome | Subgroups | No. of studies | Effects model | HR (95% CI) | p | Heterogeneity | |
|---|---|---|---|---|---|---|---|
I2 (%) | p | ||||||
OS | All | 10 | Random | 1.44 (1.23, 1.69) | 0.001 | 88.0 | 0.001 |
 Ethnicity | Asian | 3 | Random | 2.18 (1.19, 4.00) | 0.012 | 65.3 | 0.056 |
Nonasian | 6 | Random | 1.26 (1.08, 1.46) | 0.002 | 89.5 | 0.000 | |
 Tumor type | CRPC | 8 | Random | 1.37 (1.17, 1.60) | 0.000 | 89.3 | 0.000 |
mPCa | 7 | Random | 1.75 (1.17, 2.60) | 0.006 | 90.4 | 0.000 | |
 Treatment | Radiotherapy | 2 | Random | 1.55 (0.67, 3.58) | 0.308 | 97.3 | 0.000 |
Chemotherapy | 5 | Random | 1.39 (1.00, 1.93) | 0.052 | 72.0 | 0.006 | |
Chemotherapy + ARTA | 3 | Random | 1.94 (1.03, 3.67) | 0.041 | 69.3 | 0.038 | |
 Sample size | ≤ 200 | 7 | Random | 1.09 (0.98, 1.22) | 0.098 | 71.5 | 0.002 |
> 200 | 3 | Random | 2.54 (1.55, 4.16) | 0.000 | 70.1 | 0.035 | |
 Cut off value | ≤ 580 | 5 | Random | 1.61 (1.07, 2.43) | 0.022 | 84.9 | 0.000 |
> 580 | 5 | Random | 1.85 (1.07, 3.19) | 0.028 | 82.4 | 0.000 | |
PFS | All | 6 | Random | 1.80 (1.27, 2.56) | 0.001 | 92.0 | 0.000 |
 Ethnicity | Asian | 3 | Random | 4.03 (1.07, 15.17) | 0.039 | 93.2 | 0.000 |
 Tumor type | CRPC | 3 | Random | 2.30 (0.88, 6.00) | 0.089 | 95.5 | 0.000 |
nmPCa | 3 | Random | 1.78 (0.94, 3.35) | 0.075 | 86.3 | 0.001 | |
 Treatment | Chemotherapy | 2 | Random | 1.31 (0.71, 2.41) | 0.389 | 84.9 | 0.010 |
Chemotherapy + ARTA | 2 | Random | 3.04 (0.22, 42.53) | 0.408 | 96.7 | 0.000 | |
RP | 3 | Random | 1.78 (0.94, 3.35) | 0.075 | 86.3 | 0.001 | |
 Sample size | ≤ 200 | 3 | Random | 2.30 (0.88, 6.00) | 0.089 | 95.5 | 0.000 |
> 200 | 3 | Random | 1.78 (0.94, 3.35) | 0.075 | 86.3 | 0.001 | |
 Cut off value | ≤ 580 | 3 | Random | 3.65 (0.72, 18.37) | 0.116 | 96.7 | 0.000 |
> 580 | 3 | Random | 1.19 (1.04, 1.36) | 0.010 | 0.0 | 0.599 | |